Can-Fite BioPharma up on positive data from preclinical cancer drug studies

Can Fite Biopharma

24/01/2023 13:24

** U.S.-listed shares of Israel-based Can-Fite BioPharma Ltd
 CANF.N  rise 11.7% to $5.65 premarket 
    ** Drug developer reports data from preclinical studies,
which shows its experimental drug namodenoson for potential
treatment of pancreatic cancer significantly inhibits tumor
growth as a monotherapy as well as in combination with
chemotherapy 
    ** CANF says it has filed a patent application that covers
the use of namodenoson for treatment of pancreatic cancer
    ** CANF shares fell ~49% in the past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))